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Summary
Aim.  —  To  evaluate  the  evolution  of  surgical  management  in  a  large  population  of  patients  with
Marfan syndrome.
Methods.  —  This  is  a  retrospective  study  of  patients  fulﬁlling  the  Ghent  criteria  for  Marfan  syn-
drome, who  visited  the  Centre  de  référence  national  pour  le  syndrome  de  Marfan  et  apparentés
and underwent  a  surgical  event  before  or  during  follow-up  in  the  centre.
Results.  —  One  thousand  and  ninety-seven  patients  with  Marfan  syndrome,  according  to  inter-
national  criteria,  came  to  the  clinic  between  1996  and  2010.  Aortic  surgery  was  performed  in
249 patients  (22.7%;  20  children  and  229  adults),  including  the  Bentall  procedure  in  140  patients
(56%) and  valve-sparing  surgery  in  88  patients  (35%);  a  supracoronary  graft  was  performed  in
19 patients  (7.6%),  usually  for  aortic  dissection.  During  the  past  20  years,  the  predominant
reason for  aortic  surgery  has  switched  from  aortic  dissection  to  aortic  dilatation,  while  age  at
surgery has  tended  to  increase  (from  32.4  ±  11.9  years  to  35.2  ±  12.4  years;  P  =  0.075).  Mitral
valve surgery  was  performed  in  61  patients  (5.6%;  six  children  and  55  adults),  including  37
valvuloplasties  (60.6%)  and  18  mitral  valve  replacements  (29.5%).  No  signiﬁcant  difference  was
observed when  comparing  mitral  valve  surgery  before  and  after  2000.
Conclusion.  —  Surgery  performed  in  patients  with  Marfan  syndrome  has  switched  from  emer-
gency surgery  for  aortic  dissection  to  elective  surgery  for  aortic  dilatation;  this  is  associated
with surgery  performed  at  an  older  age  despite  the  indication  for  surgery  having  decreased
from 60  mm  to  50  mm.  No  signiﬁcant  evolution  was  observed  for  mitral  valve  surgery.
© 2012  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
But.  —  Apprécier  l’évolution  de  la  prise  en  charge  chirurgicale  des  patients  présentant  un
syndrome de  Marfan.
Méthodes.  —  Étude  rétrospective  portant  sur  les  patients  qui  ont  été  vu  au  Centre  national  de
référence pour  le  syndrome  de  Marfan  et  apparentés,  remplissant  les  critères  de  Ghent  et  ayant
subi une  intervention  chirurgicale  avant  ou  pendant  leur  suivi  dans  le  centre.
Résultats.  —  Mille  quatre-vingt  dix-sept  patients  présentant  un  syndrome  de  Marfan  selon  les
critères  internationaux  ont  été  vus  entre  1996  et  2010.  La  chirurgie  aortique  a  été  pratiquée
chez 249  (22,7  %  ;  20  enfants  et  229  adultes),  soit  une  intervention  de  Bentall  (n  =  140,  56  %),
soit une  intervention  préservant  la  valve  aortique  (n  =  88,  35  %).  Chez  les  19  derniers  patients
(7,6 %),  un  tube  sus-coronaire  a  été  mis  en  place,  en  règle  pour  dissection  aortique.  Au  cours
des 20  dernières  années,  l’indication  principale  de  la  chirurgie  a  changé  de  dissection  aor-
tique à  dilatation  aortique,  ce  alors  que  l’âge  de  la  chirurgie  avait  tendance  à  augmenter
(32,4 ±  11,9  ans  vs  35,2  ±  12,4  ans,  avant  et  après  2000  ;  p  =  0,075).  La  chirurgie  valvulaire
mitrale a  été  pratiquée  chez  61  patients  (5,6  %  ;  six  enfants  et  55  adultes),  à  type  de  plastie
chez 37  (60,6  %)  et  de  remplacement  valvulaire  chez  18  (29,5  %).  Les  chiffres  restent  similaires
avant et  après  l’année  2000.
Conclusion.  — La  chirurgie  réalisée  chez  les  patients  présentant  un  syndrome  de  Marfan  et
autrefois  principalement  une  chirurgie  d’urgence  pour  dissection  est  maintenant  surtout  une
chirurgie programmée  pour  dilatation  aortique.  Cela  alors  que  les  patients  sont  opérés  plus
tard alors  que  le  seuil  chirurgical  a  baissé  de  60  à  50  mm.  Les  indications  et  le  type  de  chirurgie
mitrale n’ont  pas  évolué.
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Background
Marfan  syndrome  (MFS)  is  a  connective  tissue  disorder  with
dominant  autosomal  inheritance  and  a  prevalence  of  around
1/5000,  mostly  related  to  mutations  in  the  gene  coding  for
ﬁbrillin  1  [1].  The  cardinal  features  of  MFS  involve  the  ocular,
cardiovascular  and  skeletal  systems  [2],  but  aortic  enlarge-
ment  and  dissection,  mostly  of  the  ascending  aorta,  was
the  primary  cause  of  early  death  before  1970  [3].  Much
progress  has  been  made  in  the  understanding  of  this  dis-
ease,  with  the  recognition  of  the  role  of  ﬁbrillin  1  [1],  the
M
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as  droits  réservés.
escription  of  new  pathologies  related  to  mutations  in  trans-
orming  growth  factor-beta  (TGF-) receptors  [4—6], the
mplication  of  the  TGF- pathway  in  aneurismal  aortic  dis-
ases,  etc.  [7].  Advances  have  also  been  made  in  the  global
are  of  MFS  patients,  with  the  installation  of  ‘‘Centres  de
éférence’’  and  ‘‘Centres  de  competence’’,  through  the
‘Plan  maladies  rares’’.  In  parallel,  the  life  expectancy  of
FS  patients  has  improved  by  30  years  over  the  past  30  years
8],  probably  as  a  result  of  better  recognition  of  the  dis-
ase,  diffusion  of  medical  therapy  (including  beta-blockers)
nd  monitoring  of  the  aortic  root  diameter,  allowing  for
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reventive  aortic  root  replacement  [9,10]. However,  the
odiﬁcation  of  patient  care  during  this  period  is  not  doc-
mented  other  than  by  surgical  series,  i.e.  reﬂecting  the
volution  of  care  in  speciﬁc  high-volume  centres.  Besides,
ecause  the  populations  studied  were  usually  not  com-
letely  characterized  according  to  international  criteria,
he  series  mostly  comprise  aortic  aneurysm  patients  rather
han  MFS  patients.
Here  we  take  advantage  of  a  large  MFS  population  fol-
owed  in  a  multidisciplinary  medical  clinic  caring  for  MFS
atients  throughout  the  territory  according  to  modern  stan-
ards,  to  study  the  evolution  of  surgical  care  over  the  years.
ethods
opulation
ll  patients  who  came  to  the  Centre  de  référence  pour  le
yndrome  de  Marfan  et  apparentés  between  1996  and  2010
ere  considered  for  this  retrospective  study,  which  was  per-
ormed  using  the  patient  ﬁles.  Diagnosis  of  MFS  was  based
pon  the  Ghent  criteria,  which  were  evaluated  systemati-
ally  in  all  patients,  except  for  mutation  screening  and  dural
ctasia  detection,  which  were  performed  only  when  consid-
red  necessary  for  diagnosis  or  optimal  patient  or  family
are.  To  be  included  in  this  study,  patients  had  to  have  a
onﬁrmed  diagnosis  of  MFS  and  to  have  undergone  a  surgi-
al  event  (either  aortic  or  mitral).  This  is  therefore  a series
f  consecutive  patients  seen  in  our  outpatient  clinic  who  had
een  operated  on  because  of  MFS.
Surgery  could  have  been  performed  either  before  the
atients  came  to  the  Centre  de  référence  or  during  follow-
p,  in  different  places,  although  usually  in  France.
urgery
ortic  surgery
nly  surgery  of  the  ascending  aorta  was  considered  in  this
tudy.  Aortic  surgery  was  divided  into  supracoronary  graft-
ng  versus  replacement  of  the  sinuses  of  Valsalva.  Within
urgery  including  replacement  of  the  sinuses  of  Valsalva,
alve-sparing  surgery  was  distinguished  from  the  Bentall
rocedure  using  either  a  bioprosthesis  or  a  mechanical  aor-
ic  valve.  The  reason  for  surgery  was  also  evaluated  (aortic
issection  or  aortic  dilatation).  Because  aortic  valve  regur-
itation  is  secondary  to  aortic  dilatation  in  this  population
nd  requires  surgery  for  an  aortic  diameter  above  our  sur-
ical  threshold  (50  mm),  aortic  surgery  was  considered  to
e  performed  for  aortic  dilatation  even  if  in  a  few  patients
ortic  regurgitation  may  have  been  the  revealing  factor.
itral  valve  surgery
itral  valve  replacement  was  distinguished  from  mitral
alve  preservation.
ata presentation and statistics
escriptive  data  are  presented  as  mean  value  ±  standard
eviation  or  frequency  and  percentage,  as  appropriate.  The
hi2 test  was  used  to  compare  percentages  and  the  Wilcoxon
ank-sum  test  was  used  to  compare  age  at  surgery  before  and
fter  2000.
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esults
 total  of  4218  patients  were  screened  for  MFS  in  our  clinic
etween  1996  to  2010;  57%  lived  in  Paris  or  a  close  suburb,
hile  the  remainder  came  from  all  over  the  French  terri-
ory.  Of  these,  1097  fulﬁlled  the  Ghent  criteria  for  MFS  (540
en  and  557  women);  356  were  ﬁrst  seen  as  children  (i.e.
ged  <  18  years)  and  741  were  ﬁrst  seen  as  adults;  the  mean
ge  at  last  consultation  was  32.2  ±  16.7  years.
Surgery  of  the  ascending  aorta  was  performed  in  249
atients,  i.e.  22.7%  of  the  whole  population,  comprising
0  children  (5.6%  of  the  children)  and  229  adults  (30.9%  of
he  adult  population).  Aortic  surgery  included  aortic  valve
eplacement  in  140  patients  and  aortic  valve  sparing  in  88
atients  (two  unknown).  In  the  remaining  19  patients  (7.6%),
 supracoronary  graft  was  performed,  i.e.  in  92.4%  of  the
atients,  the  sinuses  of  Valsalva  were  replaced.  The  reason
or  surgery  was  aortic  dilatation  in  67%  of  patients  and  aortic
issection  in  the  remaining  33%.  A  supracoronary  graft  was
erformed  mainly  when  aortic  dissection  was  the  reason  for
urgery  (14/19  patients).
Surgery  of  the  mitral  valve  was  performed  in  61  patients
5.6%),  comprising  six  children  (1.7%  of  the  children;  ﬁve
alvuloplasties  and  one  mitral  valve  replacement)  and  55
dults  (4.8%  of  the  adults;  37  valvuloplasties  and  18  mitral
alve  replacements).
During  the  past  20  years,  important  changes  in  surgi-
al  practice  have  occurred  (Fig.  1):  The  main  reason  for
ortic  surgery  has  changed  from  aortic  dissection  to  aor-
ic  dilatation  (which  represented  54%  of  aortic  valve  surgery
efore  2000  vs  77%  after  2000;  P  <  0.0001).  The  type  of  aortic
urgery  has  switched  from  aortic  valve  replacement  to  aor-
ic  valve-sparing  surgery  (18%  before  2000  vs  59%  after  2000;
 <  0.0001).  However,  these  changes  were  not  due  to  earlier
ortic  surgery  as  the  patients  who  had  operations  on  the
scending  aorta  before  2000  tended  to  be  slightly  younger
han  patients  operated  on  during  or  after  2000  (32.4  ±  11.9
ears  vs  35.2  ±  12.4  years;  P  =  0.076;  Fig.  2).
When  comparing  the  146  patients  who  were  operated  on
efore  their  ﬁrst  visit  to  our  centre  with  the  103  patients
perated  on  after  their  ﬁrst  visit  to  our  centre,  many  vari-
bles  differed:  age  at  ﬁrst  visit  to  our  centre  was  older
38.0  ±  11.7  years  vs  31.3  ±  12.3  years;  P  <  0.01),  reason
or  surgery  was  more  frequently  aortic  dissection  (43.0%
s  8.8%;  P  <  0.01)  and  aortic  valve  replacement  was  more
requent  (80.8%  vs  35.7%;  P  <  0.001),  whereas  surgery  was
erformed  at  a  similar  age  (33.4  ±  11.8  years  vs  34.9  ±  12.8
ears;  P  =  0.33).
The  percentage  of  mitral  valve  surgery  in  which  valvu-
oplasty  was  performed  remained  roughly  stable  over  the
ears  (65%  of  mitral  valve  surgery  before  2000  vs  73%  after
000;  P  =  0.46;  Fig.  3).  The  age  at  which  surgery  was  per-
ormed  was  also  similar  before  and  after  2000  (29.5  ±  11.5
ears  vs  30.4  ±  15.5  years;  P  =  not  signiﬁcant;  Fig.  2).
iscussionatients  with  MFS  have  beneﬁted  from  many  improvements
n  both  diagnosis  and  care.  Diagnosis  has  improved  due  to
ncreased  awareness  of  the  disease  in  the  medical  popula-
ion  and  better  organization  of  medical  care  for  patients
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Figure 1. Evolution of aortic surgery as a function of time. A. Evolution of surgical techniques: percentage of the population operated
on with different surgical techniques according to year. Valve-sparing aortic surgery has become the preferred technique and the Bentall
procedure is becoming less frequent; supracoronary grafting remains marginal. B. Evolution of reasons for surgery: percentage of the
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wpopulation operated on for aortic dissection or dilatation according
to aortic dilatation.
with  rare  diseases,  along  with  voluntary  political  action  in
some  countries  such  as  France.  This  has  led  to  an  increased
rate  of  familial  screening,  secondary  to  an  increased  under-
standing  of  the  genetic  nature  of  the  disease  by  the  medical
community,  as  well  as  increased  availability  of  genetic  test-
ing,  which  is  used  more  and  more  [11]. Echocardiography
is  now  readily  available  and  aortic  root  follow-up  is  stan-
dardized  [12], with  clear  recommendations  being  issued
[9,13].  Medical  care  has  been  standardized,  with  an  indica-
tion  for  beta-blockade  in  all  patients  with  MFS,  or  calcium
antagonists  [14]  when  beta-blockers  are  not  tolerated.  New
therapies  such  as  losartan  are  being  tested  in  randomized
trials  [15—18]. Aortic  root  surgery  has  transformed  the  prog-
nosis  of  patients  with  MFS:  before  the  Bentall  procedure
was  described  in  1968  [19]  survival  was  limited  by  aortic
complications  [3].  Since  the  description  of  the  initial  tech-
nique,  numerous  improvements  have  been  proposed  and
more  recently,  aortic  valve-sparing  surgery  techniques  have
been  described  [20—23]. Both  medical  and  surgical  improve-
ments  have  led  to  an  increase  in  survival  expectancy  of  at
least  30  years  over  the  past  30  years  [8].
w
a
eear. The reason for aortic surgery switched from aortic dissection
From  the  surgical  viewpoint,  reports  have  been  issued
y  surgical  reference  centres,  indicating  the  change  in
heir  practice  from  the  classical  Bentall  procedure  to  valve-
paring  surgery:  in  a  study  at  Johns  Hopkins  University  that
ncluded  372  patients,  61%  had  a  valve-sparing  procedure
n  the  past  8  years,  whereas  85%  received  a  Bentall  graft
uring  the  ﬁrst  24  years  of  the  study  [24], with  excellent
esults.  Other  surgical  centres  have  reported  results  after
he  Bentall  procedure  or  valve-sparing  operations,  usually  in
opulations  including  patients  with  and  without  MFS.  Recent
eports  indicate  that  valve-sparing  surgery  is  a  valuable
lternative  to  the  Bentall  procedure  [25].
Our  cohort  is  made  up  of  patients  who  came  at  least
nce  to  the  ‘‘Centre  national  de  référence’’,  as  labelled
y  the  French  Ministry  of  Health.  Patients  came  by  them-
elves  or  were  referred  to  our  centre  from  all  over  France
57%  came  from  Paris  or  a  close  suburb,  while  the  remainder
ere  from  other  parts  of  France).  Included  in  this  population
ere  patients  who  were  operated  on  in  our  centre,  as  well
s  patients  who  had  undergone  surgery  on  in  other  centres,
ither  because  they  had  been  operated  on  before  coming  to
88  
Figure 2. Age at which (A) aortic surgery or (B) mitral surgery was
performed before and after the year 2000. In red, patients operated
on before 2000; in blue, patients operated on after 2000. NS: not
signiﬁcant.
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Figure 3. Evolution of mitral surgery as a function of time: percentag
replacement according to year. No clear trend is apparent.A.  Samadi  et  al.
ur  centre  or  because  of  their  choice.  The  cohort  therefore
rovides  information  on  the  standard  care  of  the  patients
nd  care  provided  recently  by  the  more  up-to-date  centres.
hree  main  observations  can  be  made.
There  has  been  a  modiﬁcation  of  the  surgical  technique,
ith  a  switch  from  the  classical  Bentall  procedure  to  valve-
paring  operations,  while  supracoronary  grafting  remains
arginal.  Supracoronary  grafting  is  still  used  in  the  context
f  aortic  dissection  by  numerous  surgeons.
There  has  been  a  modiﬁcation  in  the  indication  for
urgery,  with  a  switch  from  aortic  dissection  to  aortic  dilata-
ion  as  the  main  reason  for  performing  surgery.  This  is
articularly  rewarding  for  cardiologists  because  it  indicates
hat  diagnosis  is  now  made  before  an  acute  (often  dramatic)
ortic  event  reveals  the  disease  in  a  patient.  One  might  think
hat  this  would  be  associated  with  surgery  performed  at  an
arlier  age,  but  mean  age  at  surgery  tended  to  increase
hen  operations  performed  after  2000  were  compared  with
hose  performed  before  2000.  This  is  particularly  impressive
s,  during  the  same  period,  the  aortic  diameter  threshold
or  prophylactic  aortic  surgery  progressively  decreased  from
0  mm  to  50  mm  [13,24—28]  and  was  even  lower  in  some
ecommendations  [29], but  not  all  [30], including  a  recent
ecommendation  from  the  ESC  [13]. A  consensus  seems  to
ave  been  obtained  that  50  mm  is  a  reasonable  threshold
or  proposing  surgery  in  a  standard  patient  with  MFS  [31].
his  observation  may  result  from  different  factors,  the  most
ptimistic  being  that  medical  therapy  (i.e.  beta-blockade
nd  information  about  sports),  which  is  now  more  widely
sed  because  of  better  recognition  of  the  disease,  is  effec-
ively  delaying  the  need  for  aortic  surgery  in  these  patients.
ut  it  is  also  possible  that  other  factors  are  involved,  such
s  increased  awareness  of  the  disease  in  the  medical  com-
unity,  better  organization  of  care  with  the  Plan  maladies
ares  and  better  availability  of  information  for  patients,
ith  active  associations  enabling  diagnosis  in  those  with  less
evere  involvement  (e.g.  through  effective  familial  screen-
ng),  resulting  in  a  reduced  or  delayed  need  for  surgery.
There  have  been  no  signiﬁcant  modiﬁcations  in  the  rate
nd  mode  of  mitral  valve  surgery.  This  would  suggest  that
e of the population operated on with valvuloplasty or mitral valve
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no  major  improvement  in  mitral  valve  surgery  has  been
made  during  this  period.  We  have  to  recognize  ﬁrst  that
the  numbers  are  much  lower,  as  only  a  small  percent-
age  of  the  population  will  undergo  mitral  valve  surgery
whereas  almost  25%  of  our  population  have  already  under-
gone  aortic  surgery  despite  their  young  age  (32.7  years).
Furthermore,  mitral  valvuloplasty  was  described  by  Carpen-
tier  well  before  the  new  valve-sparing  surgery  for  the  aortic
root,  and  mitral  regurgitation  is  associated  with  symptoms
that  allow  recognition  of  mitral  regurgitation  whereas  aor-
tic  dilatation  remains  asymptomatic  until  aortic  dissection
occurs,  as  aortic  regurgitation  is  rarely  symptomatic  in  this
population  (because  of  moderate  severity).
Limitations
This  study  included  patients  who  came  to  the  Centre  de
référence  pour  le  syndrome  de  Marfan  et  apparentés  and
therefore  did  not  include  all  patients  with  MFS  in  the  French
territory.  It  is  true  that  recognizing  all  patients  with  MFS
remains  a  challenge,  as  indicated  by  the  fact  that  the  preva-
lence  proposed  for  the  disease  has  not  been  established
after  systematic  screening  of  an  unselected  population,
because  its  polymorphic  nature  renders  systematic  screen-
ing  cumbersome  and  practically  impossible  on  a  large  scale.
Therefore,  bias  is  possible  in  the  selection  of  the  popula-
tion  included  in  this  study  and  the  evolution  of  the  surgery
reported  here  could  also  reﬂect  evolution  in  the  referral
bias.  This  appears  to  be  unlikely,  because  also  included  were
patients  who  came  only  once  and  patients  who  were  oper-
ated  on  earlier  or  in  other  places,  and  because  the  Plan
maladies  rares  has  allowed  clear  recognition  of  the  Centres
de  références  throughout  the  territory.
Conclusions
Our  data  illustrate  that  up-to-date  care,  including  familial
screening,  yearly  echocardiographic  follow-up,  systematic
beta-blockade  and  scheduled  surgery  when  the  aortic
diameter  reaches  50  mm,  has  resulted  in  a  change  from
emergency  to  elective  surgery  in  patients  with  MFS.  It  is
probable  that  other  improvements  are  going  to  appear:  on
the  medical  side,  there  is  great  hope  for  losartan  [32]; and
on  the  surgical  side,  some  new  techniques  have  been  pro-
posed  and  are  in  the  evaluation  phase  [33].
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